Literature DB >> 21693761

Agammaglobulinemia associated with BCR⁻ B cells and enhanced expression of CD19.

A Kerry Dobbs1, Amma Bosompem, Elaine Coustan-Smith, Gayle Tyerman, Frank T Saulsbury, Mary Ellen Conley.   

Abstract

Expression of a BCR is critical for B-cell development and survival. We have identified 4 patients with agammaglobulinemia and markedly reduced but detectable B cells in the peripheral circulation. These B cells have an unusual phenotype characterized by increased expression of CD19 but no BCR. The cells are positive for CD20, CD22, and CD38, but not for Annexin 5 or activation markers, including CD69, CD83, or CD86. EBV lines derived from these B cells lack functionally rearranged immunoglobulin heavy-chain transcripts, as shown by PCR-rapid amplification of cDNA ends (PCR-RACE). Analysis of BM from 2 of the patients showed a severe reduction in the number of pro-B cells as well as pre-B cells. Functionally rearranged heavy-chain transcripts were identified, indicating that machinery to rearrange immunoglobulin genes was intact. Flow cytometry of B-lineage cells suggested accelerated acquisition of maturation markers in early B-cell precursors and increased phosphorylation of signal transduction molecules. Further, expression of TdT, a molecule that is normally down-regulated by a functional pre-BCR complex, was decreased. We hypothesize that the accelerated maturation, increased expression of CD19, and lack of a BCR were due to the constitutive activation of the BCR signal transduction pathway in these patients.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21693761      PMCID: PMC3158715          DOI: 10.1182/blood-2011-01-330472

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  50 in total

1.  Composition of precursor B-cell compartment in bone marrow from patients with X-linked agammaglobulinemia compared with healthy children.

Authors:  Jeroen G Noordzij; Sandra de Bruin-Versteeg; W Marieke Comans-Bitter; Nico G Hartwig; Rudolf W Hendriks; Ronald de Groot; Jacques J M van Dongen
Journal:  Pediatr Res       Date:  2002-02       Impact factor: 3.756

2.  B-cell maturation and antibody responses in individuals carrying a mutated CD19 allele.

Authors:  H Artac; I Reisli; R Kara; I Pico-Knijnenburg; S Adin-Çinar; S Pekcan; C M Jol-van der Zijde; M J D van Tol; L E Bakker-Jonges; J J M van Dongen; M van der Burg; M C van Zelm
Journal:  Genes Immun       Date:  2010-05-06       Impact factor: 2.676

3.  An essential role for BLNK in human B cell development.

Authors:  Y Minegishi; J Rohrer; E Coustan-Smith; H M Lederman; R Pappu; D Campana; A C Chan; M E Conley
Journal:  Science       Date:  1999-12-03       Impact factor: 47.728

4.  Clinical and molecular analysis of patients with defects in micro heavy chain gene.

Authors:  Eduardo Lopez Granados; Andrea S Porpiglia; Mary Beth Hogan; Nuria Matamoros; Silvia Krasovec; Claudio Pignata; C I E Smith; Lennart Hammarstrom; Janne Bjorkander; Bernd H Belohradsky; G Fontan Casariego; M C Garcia Rodriguez; Mary Ellen Conley
Journal:  J Clin Invest       Date:  2002-10       Impact factor: 14.808

5.  Human immunoglobulin variable region gene analysis by single cell RT-PCR.

Authors:  X Wang; B D Stollar
Journal:  J Immunol Methods       Date:  2000-10-20       Impact factor: 2.303

6.  The tetraspanin CD81 regulates the expression of CD19 during B cell development in a postendoplasmic reticulum compartment.

Authors:  Tsipi Shoham; Ranjani Rajapaksa; Claude Boucheix; Eric Rubinstein; Jonathan C Poe; Thomas F Tedder; Shoshana Levy
Journal:  J Immunol       Date:  2003-10-15       Impact factor: 5.422

7.  Polymorphisms of human CD19 gene: possible association with susceptibility to systemic lupus erythematosus in Japanese.

Authors:  K Kuroki; N Tsuchiya; B P Tsao; J M Grossman; T Fukazawa; K Hagiwara; H Kano; M Takazoe; T Iwata; H Hashimoto; K Tokunaga
Journal:  Genes Immun       Date:  2002-10       Impact factor: 2.676

Review 8.  CD19 regulates intrinsic B lymphocyte signal transduction and activation through a novel mechanism of processive amplification.

Authors:  M Fujimoto; J C Poe; M Hasegawa; T F Tedder
Journal:  Immunol Res       Date:  2000       Impact factor: 4.505

9.  Mimicry of pre-B cell receptor signaling by activation of the tyrosine kinase Blk.

Authors:  Theresa Tretter; Ashley E Ross; Dominic I Dordai; Stephen Desiderio
Journal:  J Exp Med       Date:  2003-12-08       Impact factor: 14.307

10.  Surface mu heavy chain signals down-regulation of the V(D)J-recombinase machinery in the absence of surrogate light chain components.

Authors:  Gunther R Galler; Cornelia Mundt; Mathew Parker; Roberta Pelanda; Inga-Lill Mårtensson; Thomas H Winkler
Journal:  J Exp Med       Date:  2004-06-01       Impact factor: 14.307

View more
  4 in total

1.  Mutations in Bruton's tyrosine kinase impair IgA responses.

Authors:  Noriko Mitsuiki; Xi Yang; Sophinus J W Bartol; Christina Grosserichter-Wagener; Yoshiyuki Kosaka; Hidetoshi Takada; Kohsuke Imai; Hirokazu Kanegane; Shuki Mizutani; Mirjam van der Burg; Menno C van Zelm; Osamu Ohara; Tomohiro Morio
Journal:  Int J Hematol       Date:  2015-01-15       Impact factor: 2.490

2.  A recurrent dominant negative E47 mutation causes agammaglobulinemia and BCR(-) B cells.

Authors:  Bertrand Boisson; Yong-Dong Wang; Amma Bosompem; Cindy S Ma; Annick Lim; Tatiana Kochetkov; Stuart G Tangye; Jean-Laurent Casanova; Mary Ellen Conley
Journal:  J Clin Invest       Date:  2013-11       Impact factor: 14.808

3.  Agammaglobulinemia and absent B lineage cells in a patient lacking the p85α subunit of PI3K.

Authors:  Mary Ellen Conley; A Kerry Dobbs; Anita M Quintana; Amma Bosompem; Yong-Dong Wang; Elaine Coustan-Smith; Amber M Smith; Elena E Perez; Peter J Murray
Journal:  J Exp Med       Date:  2012-02-20       Impact factor: 14.307

Review 4.  Rationale of anti-CD19 immunotherapy: an option to target autoreactive plasma cells in autoimmunity.

Authors:  Henrik E Mei; Stefanie Schmidt; Thomas Dörner
Journal:  Arthritis Res Ther       Date:  2012-11-08       Impact factor: 5.156

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.